MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
OpGen Cash Conversion Cycle 2011-2026 | OPGN
Annual Cash Conversion Cycle OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.66 | 33 | 483 | 318 | 20.3 | 192 | -167 | -106 | -196 | -266 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 483 | -266 | 31.5 |
Quarterly Cash Conversion Cycle OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 46.5 | - | - | - | - | - | - | 441 | 497 | 568 | - | 304 | 605 | 1.29 K | - | 489 | 492 | 184 | - | 56.4 | 50.1 | 90.3 | - | 79.9 | 51.3 | 42.1 | - | 61.8 | 43.2 | 63.8 | - | 99.1 | 105 | 79.9 | - | 65.2 | 41.9 | 51.8 | - | 63.1 | 165 | 114 | - | 55.1 | 42.9 | 21 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 K | 21 | 205 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
224 | $ 8.87 | 2.9 % | $ 591 M | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 151.97 | -2.34 % | $ 7.53 B | USA |
 |
Castle Biosciences
CSTL
|
45.9 | $ 25.83 | 1.06 % | $ 717 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.32 | 1.82 % | $ 923 M | USA |
 |
DexCom
DXCM
|
134 | $ 66.34 | 3.27 % | $ 25.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
42.5 | $ 103.85 | 0.27 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
42.4 | $ 14.95 | 1.22 % | $ 452 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 17.29 | -3.3 % | $ 2.24 B | USA |
 |
Guardant Health
GH
|
79.6 | $ 87.18 | 1.98 % | $ 10.9 B | USA |
 |
Anixa Biosciences
ANIX
|
275 | $ 2.84 | 0.35 % | $ 92.2 K | USA |
 |
Danaher Corporation
DHR
|
77.5 | $ 191.39 | 2.17 % | $ 136 B | USA |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
62 | $ 97.61 | -0.73 % | $ 8.05 B |  Irlanda |
 |
IQVIA Holdings
IQV
|
73.9 | $ 164.89 | 0.1 % | $ 28.3 B | USA |
 |
Illumina
ILMN
|
142 | $ 119.28 | 0.29 % | $ 19 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 198.94 | -0.38 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
111 | $ 111.83 | 0.28 % | $ 34 B | USA |
 |
BioNano Genomics
BNGO
|
225 | $ 1.11 | - | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
207 | $ 8.42 | -6.44 % | $ 239 M |  Israel |
 |
Lantheus Holdings
LNTH
|
97.3 | $ 78.5 | -1.25 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
299 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 453.64 | 0.72 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 198.71 | 2.13 % | $ 24.7 B |  Schweiz |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
Neogen Corporation
NEOG
|
150 | $ 9.11 | 0.22 % | $ 1.98 B | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 17.4 | 5.33 % | $ 389 M | USA |
 |
NeoGenomics
NEO
|
82.4 | $ 8.24 | 4.57 % | $ 1.06 B | USA |
 |
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
81.5 | $ 197.68 | 5.23 % | $ 19.5 B | USA |
 |
OPKO Health
OPK
|
242 | $ 1.19 | - | $ 826 M | USA |
 |
Pacific Biosciences of California
PACB
|
185 | $ 1.36 | 2.26 % | $ 408 M | USA |